Progesterone and cerclage reduce prematurity. the international collaborative for cerclage longitudinal evaluation and research (IC-CLEAR)

Tolosa, Jorge E.; Boelig, Rupsa C.; Bell, Joseph; Martinez-Baladejo, Maria T.; Stoltzfus, Jill; Cruz, Yuri; Tymon, Jennifer; Berghella, Vincenzo; Mateus, Julio; Quiñones, Joanne N.; Galeano-Herrera, Santiago; Pereira, Leonardo; Burwick, Richard M.; Lopez-Torres, Luisa; Valencia, Catalina

doi:10.1016/j.ajog.2022.11.031

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of this 15-mm threshold is directly supported by the earlier Owen et al 28 study. [29][30][31]…”

Section: Singleton Pregnancy Prior Spontaneous Preterm Birthmentioning

confidence: 99%

“…It is important to note that for women who receive an ultrasound-indicated cerclage, there are data favoring co-treatment with vaginal progesterone, so this can also be considered in the setting of shared decision making. [29][30][31]…”

Section: Multiple Gestationmentioning

confidence: 99%

“…36 As noted, some data favor co-treatment of patients with cerclage and vaginal progesterone. [29][30][31] In addition, patients with cervical dilation in the absence of preterm contractions before 24 weeks of gestation are candidates for physical examination-indicated cerclage, and this recommendation remains unchanged.…”

Section: Cervical Insufficiencymentioning

confidence: 99%

See 2 more Smart Citations

Reassessing Preterm Birth Prevention After the Withdrawal of 17-α Hydroxyprogesterone Caproate

Heyborne

2023

Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

The U.S. Food and Drug Administration has recently withdrawn approval for 17-α hydroxyprogesterone caproate for prevention of recurrent preterm birth, and recent studies have called into question benefits of the pessary in the setting of a short cervix. Obstetric health care professionals are once again left with limited remaining options for preterm birth prevention. This narrative review summarizes the best current evidence on the use of vaginal progesterone, low-dose aspirin, and cerclage for the prevention of preterm birth; attempts to distill possible lessons learned from studies of progesterone and pessary, as well as their implementation into practice; and highlights areas where inroads into preterm birth prevention may be possible outside of the progesterone–aspirin–cerclage paradigm.

show abstract

“…The use of this 15-mm threshold is directly supported by the earlier Owen et al 28 study. [29][30][31]…”

Section: Singleton Pregnancy Prior Spontaneous Preterm Birthmentioning

confidence: 99%

Section: Multiple Gestationmentioning

confidence: 99%